Myasthenia gravis is an autoimmune disease characterised by muscle weakness due to impaired neuromuscular transmission. Circulating antibodies specific to acetylcholine receptor (AchR) of the neuromuscular junctions can be detected in many patients with myasthenia gravis.1 Antibodies to AchR are believed to cause the pathophysiology of myasthenia gravis. 23 Anticholinesterase drugs, corticosteroids, and immunosuppressive drugs have been regarded as the main treatment strategies for myasthenia gravis. 4 Immunoadsorption plasmapheresis has also been developed and its usefulness has been confirmed in adults. 5 (fig 2) . Serum immuno-nia gravis of childhood. No side effects were globulins and complements decreased as seen. Immunoadsorption plasmapheresis may follows: IgG from 21-4 to 15-5 g/l, IgA from be superior to plasma exchange as a treatment 4-4 to 3 0 g/l, IgM from 6-9 to 3-7 g/l, C3 from of myasthenia gravis because plasma prepara-1-7 to 1-2 g/l, and C4 from 032 to 0 16 g/l. tions are not used and there is less non-selective Thus 30-50% of immunoglobulins and reduction of immunoglobulins. complements were adsorbed. Fibrinogen conCorticosteroids are widely used in the centrations decreased from 3-3 to 1 1 g/l. No treatment of myasthenia gravis and are effective clinical symptoms of immunodeficiency or in most patients.4 9 13 Corticosteroids have tending to bleed were developed. On 24 June several side effects such as cataracts, glaucoma, 1992 extended thymectomy was performed, and diabetes mellitus, however. Of the side and there has been no recurrence of the bulbar effects, the suppressive influence on bone and ocular symptoms.
growth is particularly important in children. In addition, an exacerbation in myasthenic weakness occurs in approximately 50%/ of patients Discussion treated with corticosteroids.9 Therefore cortiWe treated two children with severe gener-costeroids should be used carefully and we alised myasthenia gravis with immuno-should try to reduce the total amount used in adsorption plasmapheresis and a remarkable the treatment of myasthenia gravis of childimprovement of bulbar symptoms and gener-hood. In our patients a rapid improvement in alised muscle weakness was rapidly achieved. bulbar symptoms and generalised muscle weakRemission was attained without any severe side ness was achieved and early deterioration was effects from the treatment and early deteriora-not observed. A rapid improvement in symption did not develop.
toms may shorten the duration of corticosteroid Myasthenia gravis is an autoimmune disease treatment. Thus long term repeated immunocaused by antibodies to AchR.' These anti-adsorption plasmapheresis may be useful in the bodies are postulated to mediate inactivation reduction of the total amount of corticosteroids. or destruction of AchR. Antibodies to AchR
Thymic enlargement was suggested in our are not necessarily detectable in all children first patient. Fortunately, this patient improved dramatically with immunoadsorption plasmapheresis treatment, corticosteroids, and anticholinesterase drugs. The benefit of thymectomy for patients with myasthenia gravis has been widely recognised. In childhood, however, the functions of the thymus are not fully understood and thymectomy in children with myasthenia gravis is controversial. Batocchi et al reported 59 children with myasthenia gravis and no patients under 9 years of age had a thymectomy. 9 Our experience with those two patients indicates the effectiveness and safety of immunoadsorption plasmapheresis for severe generalised myasthenia gravis of childhood. Refractory myasthenia gravis of childhood and early onset generalised myasthenia gravis await better treatments.14 15 Further studies are expected to confirm that immunoadsorption plasmapheresis treatment may also be useful in these types of myasthenia gravis.
severe generalised myasthenia gravis. 
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